About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)

NCT00664066·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Shire

Age

Any age

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Adult patients must have established Chronic Kidney Disease (CKD) and be willing and able to provide written informed consent.
Patients must already be receiving DYNEPO treatment at time of study entry.
Patients who are likely to receive DYNEPO for at least 1 year.

You may not be if

Known intolerance to EPO of any of its excipients
Known of suspected Pure Red Cell Aplasia (PRCA)

The record

StatusTerminated

PhaseNo phase

Taking part3

StartedApr 2008

UpdatedJun 25, 2021

Conditions

Anemia Kidney Diseases Renal Failure, Chronic Kidney Failure, Chronic

Where2

Nephrologische Zentrum Villingen-Schwenningen
Villingen-Schwenningen, Baden-Wurttemberg, Germany
Hanse-Klinikum Stralsund
Stralsund, Germany

Clareo Health | DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)